Seagen Inc.
- Country
- πΊπΈUnited States
- Ownership
- Public, Subsidiary
- Established
- 1998-01-01
- Employees
- 3.2K
- Market Cap
- -
- Website
- http://www.seagen.com
A Safety Study of SGN-CD19A for B-Cell Lymphoma
- Conditions
- Lymphoma, FollicularLymphoma, Large B-Cell, DiffuseBurkitt LymphomaPrecursor B-cell Lymphoblastic Leukemia-LymphomaLymphoma, Mantle-Cell
- Interventions
- First Posted Date
- 2013-02-07
- Last Posted Date
- 2017-10-19
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT01786135
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈCity of Hope National Medical Center, Duarte, California, United States
πΊπΈStanford Cancer Center, Stanford, California, United States
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas
- Conditions
- T-Cell LymphomaAnaplastic Large-Cell LymphomaNon-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2013-01-28
- Last Posted Date
- 2021-11-30
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 452
- Registration Number
- NCT01777152
- Locations
- πΊπΈ
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
πΊπΈCity of Hope National Medical Center, Duarte, California, United States
πΊπΈStanford Cancer Center, Stanford, California, United States
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
- Conditions
- Hodgkin DiseasePeripheral T Cell Lymphoma
- Interventions
- First Posted Date
- 2012-10-30
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 131
- Registration Number
- NCT01716806
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈUniversity of South Alabama - Mitchell Cancer Institute, Mobile, Alabama, United States
πΊπΈAlaska Urological Institute, Anchorage, Alaska, United States
A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
- First Posted Date
- 2012-09-03
- Last Posted Date
- 2014-01-28
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT01677390
- Locations
- πΊπΈ
Stanford Cancer Center, Stanford, California, United States
πΊπΈRocky Mountain Cancer Centers - Midtown, Denver, Colorado, United States
πΊπΈKarmanos Cancer Institute / Wayne State University, Detroit, Michigan, United States
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
- Conditions
- Acute Myeloid LeukemiaAcute Lymphoid LeukemiaAnemia, Refractory, With Excess of BlastsSolid Tumors
- Interventions
- First Posted Date
- 2011-10-28
- Last Posted Date
- 2016-03-04
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT01461538
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈCity of Hope, Duarte, California, United States
πΊπΈPMK Medical Group Inc., DBA Ventura County Hematology Oncology Specialists, Oxnard, California, United States
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
- Conditions
- Lymphoma, Non-HodgkinLymphoma, B-CellLymphoma, Large B-Cell, DiffuseLymphoma, T-Cell
- Interventions
- First Posted Date
- 2011-08-23
- Last Posted Date
- 2016-11-28
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 176
- Registration Number
- NCT01421667
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈCity of Hope, Duarte, California, United States
πΊπΈPMK Medical Group Inc., DBA Ventura County Hematology Oncology Specialists, Oxnard, California, United States
A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms
- Conditions
- Lymphoma, Large-Cell, AnaplasticLymphoma, NK-cellLymphoma, T-cell
- Interventions
- First Posted Date
- 2011-03-07
- Last Posted Date
- 2017-06-28
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT01309789
- Locations
- πΊπΈ
UAB Comprehensive Cancer Center, Birmingham, Alabama, United States
πΊπΈCity of Hope National Medical Center, Duarte, California, United States
πΊπΈStanford Cancer Center, Stanford, California, United States
A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001
- Conditions
- Lymphoma, Non-HodgkinDisease, HodgkinLymphoma, Large-Cell, AnaplasticLymphoma, T-Cell, Cutaneous
- First Posted Date
- 2010-09-08
- Last Posted Date
- 2020-09-21
- Lead Sponsor
- Seagen Inc.
- Registration Number
- NCT01196208
- Locations
- πΊπΈ
Stanford Cancer Center, Stanford, California, United States
πΊπΈDana-Farber Cancer Institute, Boston, Massachusetts, United States
πΊπΈMD Anderson Cancer Center / University of Texas, Houston, Texas, United States
A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma
- First Posted Date
- 2010-07-21
- Last Posted Date
- 2013-08-27
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT01166490
- Locations
- πΊπΈ
TGen Clinical Research Service at Scottsdale Healthcare, Scottsdale, Arizona, United States
πΊπΈUniversity of California at San Francisco, San Francisco, California, United States
πΊπΈUniversity of Chicago, Chicago, Illinois, United States
A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)
- First Posted Date
- 2010-04-09
- Last Posted Date
- 2021-05-14
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 329
- Registration Number
- NCT01100502
- Locations
- πΊπΈ
City of Hope National Medical Center, Duarte, California, United States
πΊπΈUniversity of California at San Francisco, San Francisco, California, United States
πΊπΈStanford Cancer Center, Stanford, California, United States